Corporate Events

Chugai Pharmaceutical Co., Ltd. announced that Eli Lilly and Company issued a press release on August 7, 2025 (local time) regarding the positive topline Phase 3 results from ATTAIN-1, evaluating the efficacy and safety of orforglipron compared to placebo in adults with obesity, or overweight with a weight-related medical problem and without diabetes. In the first Phase 3 trial of the ATTAIN program, ATTAIN-1 trial (n=3,127), orforglipron, taken once per day without food and water restrictions, achieved the primary and all key secondary endpoints compared to placebo. Participants taking the highest dose of orforglipron lost an average of 27.3 lbs (12.4kg) (12.4%) at 72 weeks using the efficacy estimand. In a key secondary endpoint, 59.6% of participants taking the highest dose of or forglipron lost at least 10% of their body weight, while 39.6% lost at least 15% of their body weight. The overall safety profile of orforglipron in ATTAIN-1 was consistent with the established GLP-1 receptor agonist class. The most commonly reported adverse events were gastrointestinal-related (nausea, constipation, diarrhea, vomiting, dyspepsia) and generally mild to moderate in severity. Treatment discontinuation rates due to adverse events were 5.1% (6 mg), 7.7% (12 mg) and 10.3% (36 mg) for orforglipron vs. 2.6% with placebo. The overall treatment discontinuation rates were 21.9% (6 mg), 22.5% (12 mg) and 24.4% (36 mg) fororforglipron vs. 29.9% with placebo. No hepatic safety signal was observed. The detailed ATTAIN-1 results will be presented next month at the European Association for the Study of Diabetes (EASD) Annual Meeting 2025 and published in a peer-reviewed journal. More results from the ATTAIN Phase 3 clinical trial program will be shared later this year, along with findings from the ACHIEVE Phase 3 clinical trial program evaluating orforglipron for adults with type 2 diabetes. Eli Lilly expects to submit orforglipron for weight management to global regulatory agencies by the end of this year.

Chugai Pharmaceutical Co., Ltd. announced that it resolved at the Board of Directors meeting held on July 24, 2025 to construct a new laboratory building (hereinafter "UKX") at Ukima Site (Kita-ku, Tokyo) to strengthen manufacturing process development capabilities for small, mid-size molecule drugs and biopharmaceuticals, as well as to promote environmental measures. Under its growth strategy TOP I 2030, Chugai aims to double R&D output and launch global inhouse products every year. The number of projects with highly challenging process development is increasing, including mid-size molecules and antibodies leveraging its proprietary antibody engineering technologies, and their success is key. To facilitate rapid entry into clinical trials and accelerate development, enhancement of its process development capabilities has become an urgent priority. Additionally, addressing initiatives for phasing out of halogenated hydrocarbons and CO2 emission reduction is an important challenge under its Mid-Term Environmental Goals 2030. To address these challenges, Chugai has decided to construct UKX at Ukima Site. UKX is designed as an environmentally friendly building in addition to expanding laboratory, and will be constructed on the west side of current Ukima Site for which a purchase agreement was concluded in October 2022. UKX will feature an office design that activates cross-functional communication for process development and will leverage lab automation to improve research efficiency. These initiatives will foster innovation and research productivity, further accelerating the establishment of manufacturing processes for Active Pharmaceutical Ingredients (APIs), which are becoming increasingly complex. This capital investment is not expected to affect the consolidated financial forecast for the fiscal year ending December 2025, announced on January 30, 2025.

Chugai Pharmaceutical Co., Ltd. and Gero PTE. LTD. announced that they have entered into a joint research and license agreement to develop novel therapies for age-related diseases. In this collaboration, Chugai will create novel antibody drug candidates using its proprietary antibody engineering technologies for new drug targets discovered by Gero through analysis of human datasets using their unique AI target discovery platform. Under this agreement, Gero grants Chugai exclusive worldwide rights for the creation, research, development, manufacturing, and commercialization of antibodies for the identified targets. In addition to an upfront payment, Chugai will potentially pay up to approximately 250 million USD in total if predetermined development or sales milestones are achieved. If Chugai successfully launches a product, it will also pay royalties on sales to Gero.

Chugai Pharmaceutical Co., Ltd. Presents at BIO International Convention 2025, Jun-17-2025 02:30 PM. Venue: Boston Convention and Exhibition Center, Boston, Massachusetts, United States. Speakers: Yumiko Asano, Head of Chugai Partnering.

Rani Therapeutics Holdings, Inc. announced the company has entered into a Research Agreement on 13th August, 2024, for two molecules with undisclosed targets provided by Chugai Pharmaceutical Co. Ltd. The full analysis confirms the RaniPill®? delivery demonstrated comparable bioavailability to the subcutaneous route of delivery for both molecules studied.

To explain the overall picture of drug discovery open innovation strategy under TOP I 2030 and the distinctive features of Chugai's open innovation approach, including examples of activities

Chugai Pharmaceutical Co., Ltd. Presents at Essential Protein and Antibody Engineering Summit, May-12-2025 . Venue: Boston, United States. Speakers: Takayuki Kamikawa.

Cambridge Healthtech Institute, Inc., Essential Protein and Antibody Engineering Summit, May 12, 2025 through May 16, 2025. Venue: Boston, United States.

Chugai Pharmaceutical Co., Ltd., ¥ 75.0, Cash Dividend, Jun-27-2025

Chugai Pharmaceutical Co., Ltd., ¥ 50.0, Cash Dividend, Jun-27-2025

Chugai Pharmaceutical Co., Ltd., Board Meeting, Mar 27, 2025. Agenda: To dispose treasury shares.

Information Meeting on Lunsumio

Tour of the "FJ3" Manufacturing Building for Low and Mid-size Molecule API at Fujieda Plant

Chugai Pharmaceutical Co., Ltd. provided dividend guidance for the End of fiscal year ending December 31, 2025 of JPY 125.00 per share as compared to JPY 57.00 per share paid a year ago. Breakdown of dividends per share for end of the fiscal year ending Dec. 2025: regular dividend, ¥50.00; special dividend, ¥75.00 (Special dividend for the company's 100th Anniversary).

Chugai Pharmaceutical Co., Ltd. provided special dividend guidance for end of second quarter of fiscal year ending December 31, 2025 of JPY 75.00 per share. For end of the fiscal year ending December 31, 2025, the company provided special dividend guidance of JPY 75.00 per share.

Chugai Pharmaceutical Co., Ltd. announced dividend for the End of fiscal year 31 December 2024 of JPY 57.00 per share. Date on which Dividend Payments to Commence: March 28, 2025. For the End of second quarter of fiscal year ending 31 December 2025, the company provided dividend guidance of JPY 50.00 per share as compared to of JPY 41.00 per share paid a year ago.

Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year ending December 31, 2025. For the year, company expects revenues of JPY 1,190,000 million, Core operating profit of JPY 570,000 million, Core net income of JPY 410,000 million and Core earnings per share of JPY 250.00.

Chugai Pharmaceutical Co., Ltd. Presents at 15th World Bispecifics Summit, Sep-04-2024 04:00 PM. Venue: Boston, Massachusetts, United States. Speakers: Yuri Teranishi-Ikawa, Principal Scientist.

Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025, at 10:00 Tokyo Standard Time. Location: Hotel Tokyo - 2F Aoi 1-1, Marunouchi 1-chome, Chiyoda-ku Tokyo Japan Agenda: To consider the Business Report for the Business Term (January 1, 2024 to December 31, 2024), Non-Consolidated Financial Statements for the Business Term, Consolidated Financial Statements for the Business Term, and the Report on the Results of Audit of the Consolidated Financial Statements by the Accounting Auditor and Audit & Supervisory Board; to consider the Appropriation of Surplus; to consider the Election of Nine (9) Directors; and to consider other matters.

Chugai Pharmaceutical Co., Ltd., Board Meeting, Jan 30, 2025. Agenda: To consider the Distribution of Retained Earnings.

Chugai Pharmaceutical Co., Ltd. Presents at Veeva R&D and Quality Summit, Oct-31-2024 04:20 PM. Venue: Tokyo, Japan. Speakers: Moena Ito, Regulatory Affairs Department.

CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519) on January 14, 2025. Upon completion, CHEPLAPHARM group will solely market Tarceva after transferring assets related to Tarceva that are owned by Roche Group and Chugai Pharmaceutical Co., Ltd. (TSE:4519), including the marketing authorization and intellectual property rights (patents and trademarks, etc.). The transfer of the marketing authorization is scheduled to take place on April 1, 2025, and the sales transfer is scheduled to take place in June 2025.

Araris Biotech AG announced they have entered a Research Collaboration and Option to License Agreement under which Araris will use its proprietary linker-conjugation platform, AraLinQ™, to generate novel ADCs using antibodies against undisclosed targets provided by Chugai Pharmaceutical Co., Ltd. Under the terms of the RCO Agreement, Chugai will pay an upfront fee, fund all research activities and after exercising the option be solely responsible for the development, manufacturing and global commercialization activities. Upon achievement of certain development, regulatory and commercial milestones by Chugai after exercising the option, Araris will be eligible for potential milestone payments of approximately USD 780 million, plus royalties on net sales of products.

I.I.R Ltd., Antibody Engineering & Therapeutics US, Dec 14, 2024 through Dec 17, 2024. Venue: United States.

R&D meeting

Chugai Pharmaceutical Co., Ltd. Presents at BIO-Europe 2024, Nov-04-2024 04:45 PM. Venue: Stockholmsmässan, Stockholm, Sweden.

Chugai Pharmaceutical Co., Ltd. revised consolidated earnings guidance for the financial year ending December 31, 2024. For the year, company expects revenues of JPY 1,150,000 million against JPY 1,070,000 million previous forecast, Core operating profit of JPY 540,000 million against JPY 460,000 million previous forecast, Core net income of JPY 388,000 million against JPY 335,500 million previous forecast and Core earnings per share of JPY 236.00 against JPY 204.00 previous forecast.

Chugai Pharmaceutical Co., Ltd., Board Meeting, Oct 25, 2024. Agenda: To consider Reasons for the revision; and to consider Contents of the revision.

Biotechnology Innovation Organization, BIO International Convention 2025, Jun 16, 2025 through Jun 19, 2025. Venue: Boston Convention and Exhibition Center, Boston, Massachusetts, United States.

Sustainability Meeting

Chugai Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results at 4:00 PM, Tokyo Standard Time on Jul 24, 2025

Chugai Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results at 5:00 PM, Tokyo Standard Time on Apr 24, 2025

Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results at 5:00 PM, Tokyo Standard Time on Jan 30, 2025

Chugai Pharmaceutical Co., Ltd., Q2 2025 Earnings Call, Jul 24, 2025

Chugai Pharmaceutical Co., Ltd., 2024 Earnings Call, Jan 30, 2025

Chugai Pharmaceutical Co., Ltd., Q1 2025 Earnings Call, Apr 24, 2025

Chugai Pharmaceutical Co., Ltd. expected to report Fiscal Year 2024 results on January 30, 2025. This event was calculated by S&P Global (Created on October 17, 2024).